(Q38849324)

English

Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II.

scientific article published on 27 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 September 2017

Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II. (English)

1 reference

Europe PubMed Central

7 September 2017

6

object named as

David H Coy

1 reference

Europe PubMed Central

7 September 2017

author name string

Lichun Sun

1

1 reference

Europe PubMed Central

7 September 2017

Qingqing Qian

2

1 reference

Europe PubMed Central

7 September 2017

Guangchun Sun

3

1 reference

Europe PubMed Central

7 September 2017

L Vienna Mackey

4

1 reference

Europe PubMed Central

7 September 2017

Joseph A Fuselier

5

1 reference

Europe PubMed Central

7 September 2017

Cui-Yun Yu

7

1 reference

Europe PubMed Central

7 September 2017

publication date

27 July 2015

1 reference

Europe PubMed Central

7 September 2017

Journal of Drug Targeting

1 reference

Europe PubMed Central

7 September 2017

24

1 reference

Europe PubMed Central

7 September 2017

169-177

1 reference

Europe PubMed Central

7 September 2017

2

1 reference

Europe PubMed Central

7 September 2017

Valproic acid enhances bosutinib cytotoxicity in colon cancer cells

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Molecular and therapeutic potential and toxicity of valproic acid

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Clinically relevant concentrations of valproic acid modulate melatonin MT(1) receptor, HDAC and MeCP2 mRNA expression in C6 glioma cells

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Notch signaling proteins: legitimate targets for cancer therapy

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Mechanisms of action of valproate: a commentatory

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy.

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Neuroendocrine tumors of the diffuse neuroendocrine system

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Carcinoid tumors.

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Carcinoid--a comprehensive review

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Notch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Somatostatin receptor-targeted anti-cancer therapy

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Investigation of cancer cell lines for peptide receptor-targeted drug development

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Somatostatin receptors in bronchopulmonary neuroendocrine neoplasms: new diagnostic, prognostic, and therapeutic markers.

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Somatostatin receptor expressing bilateral ovarian metastases detected by (68)Ga DOTANOC PET/CT.

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Could valproic acid be an effective anticancer agent? The evidence so far.

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Histone deacetylase is a target of valproic acid-mediated cellular differentiation

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Overexpression of COX-2 in human osteosarcoma cells decreases proliferation and increases apoptosis

1 reference

https://api.crossref.org/works/10.3109%2F1061186X.2015.1066794

21 January 2018

Identifiers

10.3109/1061186X.2015.1066794

1 reference

Europe PubMed Central

7 September 2017

1 reference

Europe PubMed Central

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38849324&oldid=1505320221"